Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a 0.2% w/w cream for topical use. It is indicated for the field-directed treatment of actinic keratosis, a precancerous skin lesion caused by chronic sun exposure, and is applied to the affected skin areas of adult patients under medical supervision.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Metvix is employed in dermatology for the photodynamic treatment of actinic keratosis.

Actinic keratosis (single lesions): clears individual precancerous lesions. Actinic keratosis (field therapy): treats multiple lesions across a sun‑damaged area, reducing overall lesion burden. Field cancerization: addresses subclinical dysplastic cells in chronically sun‑exposed skin.

Adverse reactions to Metvix are generally localized to the application site and may vary in severity.

Common Side Effects: - Erythema (redness of the skin) - Edema (swelling) - Pain or burning sensation - Crusting or scaling

Serious or Rare Side Effects: - Severe photosensitivity reaction - Allergic contact dermatitis - Infection of the treated area

When using Metvix, certain precautions should be observed to minimize risks and ensure optimal outcomes.

Avoid sun exposure: protect the treated area from direct sunlight for at least 48 hours after application. Do not apply to mucous membranes: limit use to intact skin only. Use protective clothing: wear gloves and long sleeves during and after treatment as advised. Monitor for excessive pain: discontinue use and seek medical advice if pain becomes intolerable. Store at room temperature: keep in the original packaging, protect from light and moisture.

Metvix may interact with other agents that affect photosensitivity or skin integrity.

Major Interactions (Avoid): - Systemic photosensitizing drugs (e.g., tetracyclines, sulfonamides): may increase risk of severe phototoxic reactions. - Topical retinoids applied to the same area: can enhance local irritation.

Moderate Interactions (Monitor Closely): - Oral anticoagulants: monitor for bleeding if ulceration occurs at the treatment site. - Immunosuppressive therapy: may reduce the efficacy of photodynamic treatment. - Concurrent use of other topical agents: avoid applying other creams or ointments within 24 hours of Metvix.